Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics

OBJECTIVE: Pembrolizumab has become an integral first line therapeutic agent for non-small cell lung cancer (NSCLC), but its potential predictive role in clinical and molecular characteristics remains to be clarified. Accordingly, we performed a systematic review and meta-analysis to evaluate the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenjie, Huo, Gengwei, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197372/
https://www.ncbi.nlm.nih.gov/pubmed/37202730
http://dx.doi.org/10.1186/s12885-023-10959-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197372/
https://www.ncbi.nlm.nih.gov/pubmed/37202730
http://dx.doi.org/10.1186/s12885-023-10959-3

Ejemplares similares